logo

For the Inventor, By the Inventor

Monza, Italy

Fernando Barzaghi

USPTO Granted Patents = 34

Average Co-Inventor Count = 3.2

ph-index = 6

Forward Citations = 109(Granted Patents)


Location History:

  • Monza, Milan, IT (1989)
  • Monza, IT (1980 - 1993)
  • Milan, IT (1984 - 1993)

Company Filing History:

goldMedal33 out of 854 
 
Roussel Uclaf
 patents
silverMedal1 out of 1 
 
Roussel Ucaf
 patent

Years Active: 1980-1993

Loading Chart...
34 patents (USPTO):Explore Patents
1. 5231107 - Derivatives of the oxime of 1,2,5,6-tetrahydropyridine 3-carboxaldehyde, (1993-07-27),
2. 5219873 - Compounds of 1,2,5,6-tetrahydropyridine which are useful as cholinergic (1993-06-15),
3. 5219872 - Compounds of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime which are (1993-06-15),
4. 5204479 - Derivatives of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime (1993-04-20),
5. 5204341 - 1-arylsulphonyl-2-pyrrolidone derivatives, their preparation process and (1993-04-20),
6. 5183896 - Derivatives of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime (1993-02-02),
7. 5183893 - 1-azabicycloalkane derivatives, their preparation process and their use (1993-02-02),
8. 5164514 - Derivatives of 1-arylsulphonyl-2-pyrolidinone (1992-11-17),
9. 5081130 - Derivatives of 1-arylsulphonyl-2-pyrrolidinone, their preparation (1992-01-14),
10. 5053416 - Derivatives of 1,2,5,6-tetrahydropyridine substituted by a thiazolyl or (1991-10-01),
11. 5041436 - 1-arylsulphonyl-2-piperidinone derivatives, process and intermediates (1991-08-20),
12. 5037822 - 1-arylsulphonyl-2-pyrrolidinethione or (1991-08-06),
13. 5015655 - 1-azabicycloalkane derivatives, their preparation process and their use (1991-05-14),
14. 4990531 - Derivatives of 1-arylsulphonyl-2-pyrrolidinone and their use as (1991-02-05),
15. 4948804 - Derivatives of 1-benzoyl 2-oxo 5-alkoxy pyrrolidine, their preparation, (1990-08-14),

Title: Fernando Barzaghi: A Leading Innovator in Pharmaceutical Patents

Introduction:

Fernando Barzaghi, an accomplished inventor based in Monza, Italy, has made significant contributions to the field of pharmaceuticals through his innovative work. With an impressive portfolio of 34 patents, Barzaghi's research primarily focuses on compounds related to the treatment of neurological disorders, particularly Alzheimer's disease and senile dementia.

Latest Patents:

Among his latest patents, Barzaghi has developed derivatives of the oxime of 1,2,5,6-tetrahydropyridine 3-carboxaldehyde. These compounds are designed to assist in the treatment of patients suffering from senile dementia, Alzheimer's disease, or memory defects. Specifically, his formulations include variations where R' can represent various aliphatic or aromatic groups, and compounds featuring specific substitutions that enhance their therapeutic efficacy. Notably, these patents also cover therapeutic compositions and methods for treating patients using his innovative compounds.

Career Highlights:

Throughout his career, Fernando Barzaghi has been associated with prominent pharmaceutical companies such as Roussel Uclaf and Roussel Ucaf. His work has significantly advanced the understanding and treatment of various cognitive disorders, solidifying his reputation as a leading innovator in the pharmaceutical industry.

Collaborations:

Barzaghi has collaborated with esteemed colleagues like Emilio Toja and Giulio Galliani. These partnerships have fostered an environment of innovation, allowing for the development of groundbreaking treatments and expanding the horizons of pharmaceutical research.

Conclusion:

Fernando Barzaghi's contributions to pharmaceutical innovation are noteworthy, particularly in the context of treating debilitating neurological conditions. His extensive patent portfolio exemplifies his commitment to advancing medical science and improving patient outcomes through innovative compounds. As the healthcare landscape continues to evolve, Barzaghi's work remains crucial in addressing the challenges posed by cognitive disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…